Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.53 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20366017 | 1.00 | GPR84 (0.55) | GPR84FFAR1NOD1MAPTLCK | |
| SCHEMBL7182087 | 1.00 | GPR84 (0.55) | GPR84FFAR1NOD1MAPTLCK | |
| SCHEMBL10352539 | 1.00 | GPR84 (0.55) | GPR84FFAR1NOD1MAPTLCK | |
| SCHEMBL2809182 | 1.00 | GPR84 (0.55) | GPR84FFAR1NOD1MAPTLCK | |
| SCHEMBL20447803 | 1.00 | GPR84 (0.55) | GPR84FFAR1NOD1MAPTLCK | |
| SCHEMBL25208251 | 1.00 | GPR84 (0.55) | GPR84FFAR1NOD1MAPTLCK | |
| SCHEMBL3896154 | 1.00 | GPR84 (0.55) | GPR84FFAR1NOD1MAPTLCK | |
| Hydrochloric Acid SCHEMBL15799584 | 0.98 | GPR84 (0.53) | GPR84FFAR1NOD1MAPTLCK | |
| SCHEMBL21102191 | 0.98 | GPR84 (0.52) | GPR84FFAR1NOD1MAPTLCK | |
| SCHEMBL15451410 | 0.98 | GPR84 (0.52) | GPR84FFAR1NOD1MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| CN-110520409-A | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX INC | 2019-11-29 | — | — | CN | disclosed |
| CN-108715606-A | The method of the cyclic annular ten monoamino-acid peptides of production | 诺华股份有限公司 | 2018-10-30 | — | — | CN | disclosed |
| US-9840534-B2 | Process for the manufacture of cyclic undecapeptides | NOVARTIS AG (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20160304554-A1 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | NOVARTIS PHARMA AG (CH) | 2016-10-20 | — | — | US | disclosed |
| US-20150087808-A1 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| EP-2847211-A1 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | Novartis AG (CH) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167703-A9 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | NOVARTIS AG (CH) | 2014-11-20 | — | — | WO | disclosed |
| WO-2013167703-A1 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | NOVARTIS AG (CH) | 2013-11-14 | — | — | WO | disclosed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-0852233-A1 | CYCLOSPORIN PHOSPHATE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087808-A1 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | UMPS, SAMHD1, NPEPPS | GPR84 2227/4885FFAR1 2641/4885NOD1 232/4885 |
| US-20160304554-A1 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | UMPS, SAMHD1, NPEPPS | GPR84 2227/4885FFAR1 2641/4885NOD1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.